Doxorubicin/nivolumab/talimogene laherparepvecInfectious complications, lack of efficacy and off label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1779卷 / 1期

关键词：

D O I：

10.1007/s40278-019-71372-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：108 / 108

相关论文

共 50 条

[1] Doxorubicin/nivolumab/trametinibLack of efficacy and off-label use: case report
Reactions Weekly, 2022, 1922 (1) : 240 - 240
[2] Doxorubicin/lenvatinibNausea following off-label use and lack of efficacy: case report
Reactions Weekly, 2023, 1946 (1) : 208 - 208
[3] Ipilimumab/nivolumab/trametinibGrade 2 folliculitis, lack of efficacy and off-label use : case report
Reactions Weekly, 2023, 1986 (1) : 228 - 228
[4] AntineoplasticsNeutropenia, off-label use and lack of efficacy: case report
Reactions Weekly, 2022, 1926 (1) : 69 - 69
[5] AntineoplasticsVarious toxicities, off label use and lack of efficacy: case report
Reactions Weekly, 2022, 1905 (1) : 74 - 74
[6] Multiple drugsThrombocytopenia, lack of efficacy and off label use: case report
Reactions Weekly, 2023, 1975 (1) : 268 - 268
[7] Dexamethasone/remdesivirHepatotoxicity, lack of efficacy and off label use: case report
Reactions Weekly, 2023, 1955 (1) : 154 - 154
[8] AntineoplasticsCryptococcosis, lack of efficacy and off-label use: case report
Reactions Weekly, 2022, 1923 (1) : 49 - 49
[9] AntineoplasticsEpendymosarcoma, lack of efficacy and off-label use: case report
Reactions Weekly, 2020, 1833 (1) : 50 - 50
[10] AntineoplasticsVarious toxicities, off label use and lack of efficacy: case report
Reactions Weekly, 2022, 1934 (1) : 57 - 57

← 1 2 3 4 5 →